UBS Adjusts InnoCare Pharma’s Price Target to HK$16.20 From HK$17.70, Keeps at Buy
UBS Adjusts InnoCare Pharma’s Price Target to HK$16.20 From HK$17.70, Keeps at Buy
瑞银将诺诚健华的目标股价从17.70港元调整至16.20港元，维持买入
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间